In a report released today, Derek Archila from Stifel Nicolaus reiterated a Buy rating on Selecta Biosciences (SELB), with a price target of $7. The company’s shares opened today at $2.47, close to its 52-week low of $1.41.
Archila commented:
“We are reiterating our Buy rating and $7 target price after SELB reported its 1Q19 financial and business update. There was very little new on today’s update call with management more or less reiterating timelines for the COMPARE study. The 6-month interim results from the COMPARE study (SEL-212 vs Krystexxa) remain a key event and are expected in 4Q19 with full results in 1Q20. Although the design of the study with Krystexxa monotherapy may not fully resolve the investor debate around SEL-212’s commercial opportunity, at the very least, we think it should de-risk SEL-212’s efficacy/safety profile and inform the Phase 3 design.”
According to TipRanks.com, Archila has 0 stars on 0-5 star ranking scale with an average return of -8.2% and a 33.6% success rate. Archila covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Rhythm Pharmaceuticals Inc, and Principia Biopharma Inc.
Selecta Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $8.
See today’s analyst top recommended stocks >>
Based on Selecta Biosciences’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $14.65 million. In comparison, last year the company had a GAAP net loss of $15.89 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Selecta Biosciences, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. it produces the Synthetic Vaccine Particles (SVP) platform for immune tolerance and immune stimulation.
